Mayet

Unparalleled efficiency, quality, and compliance in clinical trial vendor management and oversight.

[Mayet @MayetRx]

Exciting news! Mayet has earned the Cyber Essentials Plus certification accredited by @IASME1, showing our strong commitment to keeping your data safe. Learn more: https://t.co/gohMcSYtCv #CyberSecurity #DataPrivacy

[Mayet @MayetRx]

Enhancing web accessibility is key to our mission. We've conducted our first review, optimising with TailwindUI and addressing detailed issues. Learn about our process, manual testing, and Google's Lighthouse insights in our latest blog post. https://t.co/D4HerLsPv1
#Pharma #app

[Mayet @MayetRx]

@CyberEssentials @thrivingapp Thanks @CyberEssentials

[Mayet @MayetRx]

Keeping momentum up on our commitment to deliver best in class clinical trial vendor management software.
#pharma #biotech #compliance #quality #clinicaltrials #cybersecurity

[Cyber Essentials @CyberEssentials]

Well done to @MayetRx and @thrivingapp - both now certified to #CyberEssentials

[Cyber Essentials @CyberEssentials]

Well done to @MayetRx and @thrivingapp - both now certified to #CyberEssentials

[Mayet @MayetRx]

Excited to welcome Chris Shepherd, ex-VP at GSK and quality veteran, as our new advisor! His 30+ years of expertise will boost our product development and process efficiency. A major win for Mayet's future innovations. 🚀 More on our blog: https://t.co/rSCAzHmfjs
#growth #advisor

[Mayet @MayetRx]

Exciting times ahead for the OUD research community! It's great to see forward-thinking leaders like @SriniGRao leading the charge to explore potential treatments. We're watching with interest and support for your advocacy and hard work! 💪🔬 #OUD #clinicalresearch #innovation

[AtaiBeckley Inc @ataibeckley]

Today our co-founder and CSO @SriniGRao will give testimony alongside other experts on the scientific data of ibogaine as a potential treatment option for Opioid Use Disorder (OUD) behalf of the Kentucky Opioid Abatement Advisory Commission.

The Commission’s goal is to allocate up to $42 million over six years towards research into the treatment of OUD specifically looking into ibogaine.  

We couldn’t be prouder of Srini for speaking up, and advocating on behalf of those who need new and effective treatment options. Tune in at 2pm EST 👇
https://t.co/L8rCtEzUen

[Mayet @MayetRx]

7/7 🎈 Delve deeper into this conversation. Check out our blog post that explores this issue in detail! Share your thoughts and let's stir up a discussion of best practice. https://t.co/hBVt60Vjc0 #clinicaltrials

[Mayet @MayetRx]

1/7 🎯 Do you truly understand the difference between Vendor Level and Study Level Risk Assessments in clinical trials? They are game-changers in achieving robust vendor relationships, cost reductions, regulatory compliance, and patient safety. 🌐👥#Mayet #clinicaltrials

[Mayet @MayetRx]

6/7 🧩 Integrating both Vendor and Study Level Risk Assessments ensures a well-rounded, comprehensive risk management strategy. Stay ahead, ensure study integrity, and navigate vendor management with ease. 💼🚀 #Mayet #riskmanagement

[Akari Therapeutics @AkariTX]

Akari is on track to begin enrollment in the registrational Ph 3 study of nomacopan in pediatric HSCT-TMA by end of 2023 and is moving toward enrollment in the Ph 3 double-blind placebo-controlled study of nomacopan in adult HSCT-TMA in 2024. $AKTX https://t.co/CEQMmGzjhi

[Mayet @MayetRx]

@Bicycle_tx Great work, no doubt this will be a big deal for @Bicycle_tx in development terms

[Mayet @MayetRx]

@EBMedResearch Congratulations on the successful completion of the ProteKt study, @EBMedResearch! It's wonderful to see such positive feedback from the participants -
We're proud to be part of an industry that continually advances human health. 🎉 #clinicaltrials

[NervGen Pharma Corp. @NervgenP]

Enabling the nervous system to repair itself @NervgenP
@AbilityLab @WFLWorldRun
#Spinalcordinjury #clinicaltrials #clinicalresearch

[Mayet @MayetRx]

We are Mayet! 🚀We're transforming vendor management in clinical research. Born from the experiences of our CEO, @TomLazenby_ , we address inefficiencies with a centralised platform. Our mission? Manage risk, improve communication deliver better trials #ClinicalTrials